📄 Category

cancer biology

204 papers

Cancer biology explores the complex ways cells grow out of control, investigating the genetic mutations and environmental factors that drive tumor formation. This field seeks to understand how healthy cells transform into malignant ones and how these rogue cells spread throughout the body. By decoding these fundamental mechanisms, researchers aim to develop more effective treatments that target the disease at its source while sparing healthy tissue.

At Gist.Science, we process every new preprint published in this category directly from bioRxiv to ensure you stay ahead of the curve. Our team provides both accessible plain-language overviews and detailed technical summaries for each study, bridging the gap between raw research data and practical understanding. Whether you are a specialist or a curious reader, our goal is to make these critical findings clear and actionable.

Below are the latest papers in cancer biology, offering fresh insights into the ongoing fight against this disease.

📄 cancer biology

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML

This preclinical study demonstrates that combining the menin inhibitor ziftomenib with the XPO1 inhibitor selinexor synergistically suppresses oncogenic transcription and induces apoptosis in KMT2A-rearranged and NPM1-mutated AML by disrupting menin-chromatin interactions, thereby offering a promising strategy to overcome resistance and improve survival outcomes compared to monotherapy.

Uddin, M. H., Dhiman, S., Han, Y., Aboukameel, A., Dhillon, V., Aguillar, J., Buck, S., Deol, A., Boerner, J. L., Polin (…)2026-03-13
📄 cancer biology

Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting

This study demonstrates that engineering a novel anti-FAP single-domain antibody (VHH) into monomeric, dimeric, and Fc-fusion formats allows for the tuning of pharmacokinetic properties to optimize tumor uptake, retention, and radiation dosimetry for improved cancer theranostics targeting fibroblast activation protein.

Ott, K., Gallant, J., Kwon, O., Adeniyi, A., Bednarz, B., Barrett, K., Rosenkrans, Z., Mixdorf, J., Engle, J., Aluicio S (…)2026-03-13
📄 cancer biology

Predicting targeted- and immunotherapeutic response outcomes in melanoma with single-cell Raman Spectroscopy and AI

This study demonstrates that a non-destructive, single-cell Raman spectroscopy approach combined with machine learning can accurately differentiate melanoma cell phenotypes and predict therapeutic resistance to targeted and immunotherapies in both cell lines and patient-derived samples, offering a rapid and scalable tool for precision medicine.

Chang, K., Serasanambati, M., Ogunlade, B., Hsu, H.-J., Agolia, J. P., Stiber, A., Gu, J., Chadokiya, J., Rodriguez, G. (…)2026-03-12
📄 cancer biology

WITHDRAWN: A Druggable Tumor Suppressor and Leukemic Stem Cell Marker

This study identifies the absence of the tumor suppressor AT2R as a key marker for chemotherapy-resistant leukemic stem cells in acute myeloid leukemia, demonstrating that epigenetic silencing of AT2R drives disease progression through fatty acid metabolism and that its pharmacological activation with the agonist buloxibutid (C21) effectively inhibits leukemogenesis and enhances chemotherapy efficacy.

Pan, Y., Wang, C., Meng, X., Zhou, W., Hammer, R., Zheng, H., Hildebrandt, G., Kang, X.2026-03-11
📄 cancer biology

A MET-Targeted Variable New Antigen Receptor Theranostic for Non-Small Cell Lung Cancer

This study reports the development and preclinical validation of a shark-derived VNAR-based theranostic agent, vMET1-Fc, which enables high-contrast PET imaging and effective targeted radiotherapy for MET-altered non-small cell lung cancer with a favorable safety profile.

LeBeau, A., Minne, R., West, J., Luo, N., Nickel, K., Gunaratne, G., Ott, K., Gallant, J., Barrett, K., Mork, C., Wopat (…)2026-03-11
📄 cancer biology

Targeting NF-κB epigenetic activation and DNA repair deficiency in G34-mutant pediatric diffuse hemispheric glioma with nanoparticles combining PARP inhibition and immune stimulation mediated by CpG dinucleotides

This study demonstrates that G34-mutant pediatric diffuse hemispheric gliomas can be targeted by HDL nanoparticles co-delivering CpG dinucleotides to stimulate NF-κB-mediated immune responses and olaparib to exploit DNA repair deficiencies, thereby offering a promising therapeutic strategy for these aggressive tumors.

Haase, S., Banerjee, K., Mujeeb, A. A., Halseth, T., Liu, L., Yu, M., Sriramulu, S., Sheth, M., Raghuram, S., Lowenstein (…)2026-03-11